Insider Trading November 21, 2026 05:31 AM

Legend Biotech CEO Ingrid Zhang Buys $163,200 in Shares Near 52-Week Low

The purchase of 20,000 ordinary shares comes as the stock trades close to its yearly nadir following a steep decline.

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
LEGN

Legend Biotech CEO Ingrid Zhang acquired 20,000 ordinary shares for $163,200 on November 17, 2026, at a converted price of $8.16 per ordinary share, equivalent to $16.32 per ADS. The transaction lifts her direct holdings to 1,151,860 ordinary shares. The stock, currently at $15.25, is near its 52-week low of $15.14 and has fallen nearly 46% over the past year. The purchase coincides with mixed third-quarter 2026 results, which showed revenue slightly above expectations but a wider-than-forecast loss per share, alongside a 36% year-over-year increase in CARVYKTI net trade sales to $710 million and an improved gross-margin outlook. H.C. Wainwright reiterated a Buy rating with a $65 price target, citing progress in U.S. CARVYKTI apheresis for second- and third-line patients.

Legend Biotech CEO Ingrid Zhang Buys $163,200 in Shares Near 52-Week Low
LEGN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CEO Ingrid Zhang purchased 20,000 ordinary shares for $163,200, increasing her direct holdings to 1,151,860 ordinary shares.
  • The purchase occurred near the stock's 52-week low of $15.14, with shares down nearly 46% over the past year.
  • Third-quarter 2026 revenue slightly beat expectations, but the loss per share was much wider than forecast; CARVYKTI sales grew 36% year-over-year to $710 million.
  • H.C. Wainwright reiterated a Buy rating and $65 price target, noting progress in U.S. CARVYKTI apheresis for second- and third-line patients.

Legend Biotech Corp (NASDAQ:LEGN) disclosed that its Chief Executive Officer, Ingrid Zhang, acquired ordinary shares in the company on November 17, 2026. The total value of the purchase was $163,200.

Ms. Zhang bought 20,000 ordinary shares at a price of $8.16 per ordinary share. That per-share price reflects a converted purchase price of $16.32 per American Depositary Share (ADS), with each ADS representing two ordinary shares of the Issuer. The timing of the insider purchase is notable because the stock is currently trading at $15.25, close to its 52-week low of $15.14, after declining nearly 46% over the past year.

Following the acquisition, Ms. Zhang directly holds 1,151,860 ordinary shares of Legend Biotech Corp. According to InvestingPro analysis, the stock appears undervalued at current levels, and the company is featured on the platform's Most Undervalued list. Investors seeking deeper insights can access Legend Biotech's comprehensive Pro Research Report, available for this and 1,400+ other US equities.

In other recent news, Legend Biotech reported its third-quarter 2026 financial results, which included revenue of $359.5 million, slightly surpassing Wall Street's expectations of $358.63 million. However, the company's earnings per share were a loss of $0.13, significantly missing the forecasted loss of $0.0037. Despite the earnings miss, Legend Biotech highlighted a 36% year-over-year increase in CARVYKTI net trade sales, totaling $710 million for the quarter. The company also improved its fourth-quarter product gross-margin outlook to the high-50% range. H.C. Wainwright reiterated a Buy rating for Legend Biotech, maintaining a price target of $65.00. The firm noted Legend's progress in reaching half of the U.S. Carvykti apheresis for second- and third-line patients. These developments indicate a mixed financial performance but highlight potential growth areas for the company.

Legend Biotech's stock closed at $15.25, down $0.85 or 5.28%, on the day of the disclosure. In after-hours trading, the stock rose $0.20 or 1.30% to $15.45.

Investors seeking to determine whether LEGN is a bargain can use InvestingPro's Fair Value estimate, which runs 17 proven valuation models on the stock and provides a single number along with the potential upside or downside against the current price. The same tool can be applied to thousands of other stocks, helping investors avoid guessing which ones are already priced for perfection. More than 370,000 investors rely on InvestingPro tools from Investing.com to validate their trading ideas. Full access is currently available at 55% off for Black Friday early birds.

Risks

  • The company's earnings per share loss of $0.13 significantly missed the forecasted loss of $0.0037, indicating potential profitability challenges.
  • The stock is trading near its 52-week low and has declined nearly 46% over the past year, reflecting negative market sentiment.
  • The article does not provide details on the company's cash position, debt levels, or regulatory risks, which are important considerations for investors.

More from Insider Trading

Lipocine Director John Higuchi Purchases $225,225 in Company Stock Nov 20, 2026 Home Depot Chair Decker Offloads $6.55 Million in Shares Following Option Exercise Nov 20, 2026 Peloton Accounting Chief Offloads Shares Under Pre-Set Trading Plan Nov 20, 2026 Peloton COO Offloads $35,736 in Shares Under Pre-Set Trading Plan Nov 20, 2026 Cross Timbers Royalty Trust Director Expands Stake with $72,264 in Unit Purchases Nov 20, 2026